• Je něco špatně v tomto záznamu ?

Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk

Z. Rabekova, S. Frankova, M. Jirsa, M. Neroldova, M. Lunova, O. Fabian, M. Kveton, D. Varys, K. Chmelova, V. Adamkova, JA. Hubacek, J. Spicak, D. Merta, J. Sperl

. 2021 ; 22 (19) : . [pub] 20210929

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003660

Grantová podpora
00023001 Ministerstvo Zdravotnictví Ceské Republiky

Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups consisted of 1119 patients with liver cirrhosis of various aetiologies, and 3240 healthy individuals served as population controls. The MZ genotype was significantly more frequent in the study group (55/1119 vs. 87/3240, p < 0.0001). The MS genotype frequency was comparable in controls (32/119 vs. 101/3240, p = 0.84). MZ and MS heterozygotes had lower serum AAT level than MM homozygotes (medians: 0.90 g/L; 1.40 g/L and 1.67 g/L; p < 0.001 for both). There were significantly fewer patients with HCC in the cirrhosis group among MZ and MS heterozygotes than in MM homozygotes (5/55 and 1/32 respectively, vs. 243/1022, p < 0.01 for both). The risk of HCC was lower in MZ and MS heterozygotes than in MM homozygotes (OR 0.3202; 95% CI 0.1361-0.7719 and OR 0.1522; 95% CI 0.02941-0.7882, respectively). Multivariate analysis of HCC risk factors identified MZ or MS genotype carriage as a protective factor, whereas age, male sex, BMI and viral aetiology of cirrhosis increased HCC risk.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003660
003      
CZ-PrNML
005      
20250402154213.0
007      
ta
008      
220113s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms221910560 $2 doi
035    __
$a (PubMed)34638908
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rabekova, Zuzana $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
245    10
$a Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk / $c Z. Rabekova, S. Frankova, M. Jirsa, M. Neroldova, M. Lunova, O. Fabian, M. Kveton, D. Varys, K. Chmelova, V. Adamkova, JA. Hubacek, J. Spicak, D. Merta, J. Sperl
520    9_
$a Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups consisted of 1119 patients with liver cirrhosis of various aetiologies, and 3240 healthy individuals served as population controls. The MZ genotype was significantly more frequent in the study group (55/1119 vs. 87/3240, p < 0.0001). The MS genotype frequency was comparable in controls (32/119 vs. 101/3240, p = 0.84). MZ and MS heterozygotes had lower serum AAT level than MM homozygotes (medians: 0.90 g/L; 1.40 g/L and 1.67 g/L; p < 0.001 for both). There were significantly fewer patients with HCC in the cirrhosis group among MZ and MS heterozygotes than in MM homozygotes (5/55 and 1/32 respectively, vs. 243/1022, p < 0.01 for both). The risk of HCC was lower in MZ and MS heterozygotes than in MM homozygotes (OR 0.3202; 95% CI 0.1361-0.7719 and OR 0.1522; 95% CI 0.02941-0.7882, respectively). Multivariate analysis of HCC risk factors identified MZ or MS genotype carriage as a protective factor, whereas age, male sex, BMI and viral aetiology of cirrhosis increased HCC risk.
650    _2
$a alely $7 D000483
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a hepatocelulární karcinom $x komplikace $x genetika $7 D006528
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a jaterní cirhóza $x komplikace $x genetika $7 D008103
650    _2
$a nádory jater $x komplikace $x genetika $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sexuální faktory $7 D012737
650    _2
$a alfa-1-antitrypsin $x krev $x genetika $7 D000515
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fraňková, Soňa $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $7 xx0329475
700    1_
$a Jirsa, Milan $u Laboratory of Experimental Hepatology, Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
700    1_
$a Neroldova, Magdalena $u First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic $u Laboratory of Experimental Hepatology, Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Lunova, Mariia $u Laboratory of Experimental Hepatology, Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Fabian, Ondrej $u Clinical and Transplant Pathology Department, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Kveton, Martin $u Clinical and Transplant Pathology Department, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Varys, David $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
700    1_
$a Chmelova, Klara $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
700    1_
$a Adamkova, Vera $u Preventive Cardiology Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Hubacek, Jaroslav A $u Atherosclerosis Research Laboratory, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Spicak, Julius $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Merta, Dusan $u Anaesthesiology and Resuscitation Department, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Internal Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, 160 00 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 19 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34638908 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20250402154209 $b ABA008
999    __
$a ok $b bmc $g 1751196 $s 1154809
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 19 $e 20210929 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 00023001 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace